Nuvalent (NASDAQ:NUVL) Downgraded to “Hold” Rating by Barclays

Barclays cut shares of Nuvalent (NASDAQ:NUVL) from a strong-buy rating to a hold rating in a research note issued to investors on Tuesday,Zacks.com reports.

Several other equities analysts also recently weighed in on NUVL. Truist Financial set a $124.00 target price on Nuvalent in a research report on Tuesday. Stifel Nicolaus set a $124.00 price target on Nuvalent in a research note on Tuesday. HC Wainwright lowered Nuvalent from a “buy” rating to a “neutral” rating and set a $124.00 price target for the company. in a research note on Tuesday. Lifesci Capital lowered Nuvalent from an “outperform” rating to a “hold” rating and set a $124.00 price target for the company. in a research note on Tuesday. Finally, Guggenheim lowered Nuvalent from a “buy” rating to a “neutral” rating and cut their price target for the stock from $151.00 to $124.00 in a research note on Wednesday. Five equities research analysts have rated the stock with a Buy rating, fourteen have assigned a Hold rating and one has issued a Sell rating to the stock. Based on data from MarketBeat.com, Nuvalent presently has a consensus rating of “Hold” and a consensus target price of $131.15.

Nuvalent Stock Performance

NASDAQ NUVL opened at $123.35 on Tuesday. The company has a market capitalization of $9.74 billion, a PE ratio of -20.35 and a beta of 1.15. The business’s fifty day moving average is $103.44 and its 200 day moving average is $103.19. Nuvalent has a fifty-two week low of $71.13 and a fifty-two week high of $123.62.

Nuvalent (NASDAQ:NUVL) last released its earnings results on Thursday, May 7th. The company reported ($1.39) earnings per share for the quarter, missing the consensus estimate of ($1.35) by ($0.04). During the same quarter in the prior year, the firm posted ($1.18) earnings per share. On average, sell-side analysts forecast that Nuvalent will post -5.74 EPS for the current year.

Insider Transactions at Nuvalent

In related news, CFO Alexandra Balcom sold 11,430 shares of the business’s stock in a transaction dated Monday, June 1st. The stock was sold at an average price of $98.69, for a total value of $1,128,026.70. Following the sale, the chief financial officer directly owned 85,533 shares in the company, valued at approximately $8,441,251.77. The trade was a 11.79% decrease in their ownership of the stock. The transaction was disclosed in a filing with the Securities & Exchange Commission, which is accessible through this hyperlink. Also, insider Henry E. Pelish sold 3,093 shares of the business’s stock in a transaction dated Thursday, April 9th. The stock was sold at an average price of $104.48, for a total value of $323,156.64. Following the completion of the sale, the insider owned 65,604 shares in the company, valued at $6,854,305.92. This represents a 4.50% decrease in their ownership of the stock. Additional details regarding this sale are available in the official SEC disclosure. Insiders have sold a total of 126,953 shares of company stock valued at $12,612,264 over the last three months. Corporate insiders own 5.02% of the company’s stock.

Institutional Investors Weigh In On Nuvalent

A number of hedge funds have recently made changes to their positions in NUVL. GAMMA Investing LLC lifted its position in shares of Nuvalent by 47.6% in the fourth quarter. GAMMA Investing LLC now owns 335 shares of the company’s stock worth $34,000 after buying an additional 108 shares in the last quarter. EverSource Wealth Advisors LLC lifted its position in shares of Nuvalent by 141.3% in the first quarter. EverSource Wealth Advisors LLC now owns 333 shares of the company’s stock worth $34,000 after buying an additional 195 shares in the last quarter. Aster Capital Management DIFC Ltd purchased a new stake in shares of Nuvalent in the third quarter worth about $38,000. NBC Securities Inc. purchased a new position in Nuvalent in the fourth quarter worth about $125,000. Finally, KBC Group NV grew its position in Nuvalent by 24.1% in the fourth quarter. KBC Group NV now owns 1,527 shares of the company’s stock worth $154,000 after acquiring an additional 297 shares in the last quarter. 97.26% of the stock is currently owned by hedge funds and other institutional investors.

More Nuvalent News

Here are the key news stories impacting Nuvalent this week:

• Positive Sentiment: GSK’s $10.6 billion all-cash acquisition offer gives Nuvalent shareholders a clear exit value at $124.00 per share, which is the biggest reason the stock has increased. Reuters article on GSK deal
• Positive Sentiment: Market commentary says the deal makes strategic sense for GSK because Nuvalent adds a late-stage oncology pipeline, supporting confidence that the transaction is credible and financially meaningful. MarketBeat analysis of the acquisition
• Neutral Sentiment: Several shareholder law firms have launched investigations into whether the sale process and price are fair, which could create headline noise but does not change the announced terms. Business Wire article on investigation
• Neutral Sentiment: Analyst downgrades followed the takeover news, but their revised price targets remain close to the deal value, so these moves are unlikely to outweigh the acquisition catalyst. Analyst downgrade coverage
• Negative Sentiment: CEO James Richard Porter sold 30,000 shares, a modest negative sentiment signal that may reinforce the view that insiders have been reducing exposure ahead of the transaction. SEC insider filing

About Nuvalent

Nuvalent, Inc (NASDAQ:NUVL) is a clinical-stage precision oncology company focused on the discovery, development and commercialization of targeted therapies for patients with genetically defined cancers. Founded in 2019 and headquartered in San Diego, California, Nuvalent applies structure-guided drug design to develop small molecule inhibitors that address key oncogenic drivers. The company’s research platform integrates insights from cancer biology, medicinal chemistry and translational science to create therapies with differentiated selectivity and potency against validated targets.

Nuvalent’s lead pipeline candidates include NVL-520, a highly selective RET inhibitor designed to minimize off-target effects, and NVL-655, a potent covalent inhibitor targeting KRAS G12D mutations.